A Smarter Way to Target Brain Cancer

What if doctors could predict where a deadly brain cancer will come back and treat those areas before it does? A study published in Nature Communications May 13 suggests that may be possible.

The research tested a new way to plan radiation for glioblastoma, an aggressive brain cancer that almost always returns. Instead of treating the same areas for every patient, researchers used artificial intelligence to predict where the tumor was most likely to come back and then focused extra radiation on those high-risk spots.

Glioblastoma affects about 12,000 to 14,000 people in the United States each year and remains one of the hardest cancers to treat.

ChristianaCare Radiation Oncologist Gaurav Shukla, M.D., Ph.D., a co-author of the article, developed the idea for this clinical trial during his research training at the University of Pennsylvania and Thomas Jefferson.

“This started with a simple but important question: can we use imaging and AI to better predict where glioblastoma will return and treat those areas more precisely,” said Shukla. “This study shows that approach is feasible in real patients and gives us a strong foundation to build on.”

A More Precise Way to Deliver Radiation

Standard radiation for glioblastoma treats the tumor and a surrounding margin where cancer cells may be hiding. But doctors know the disease often returns close to the original site.

In this study, researchers used advanced MRI scans and machine learning to map where hidden cancer cells were most likely to remain after surgery. Based on those maps, they designed a radiation plan that delivered a higher dose to those areas, while still treating the surrounding brain tissue.

The study followed 20 patients with newly diagnosed glioblastoma. Researchers found the approach could be delivered safely in clinical practice and was associated with longer survival compared with a matched group of patients who received standard treatment.

From Idea to Impact

The work reflects how clinician-led ideas can move from concept to clinical research and beyond.

“At ChristianaCare, we are focused on bringing forward ideas that have the potential to change how we care for patients,” said Thomas Schwaab, M.D., Ph.D., Bank of America Endowed Medical Director of ChristianaCare’s Helen F. Graham Cancer Center & Research Institute. “This study shows what is possible when you combine clinical insight with advanced technology. It is an early but important step toward more personalized cancer treatment.”

Learn more about how the Graham Cancer Center treats brain, spinal cord and nervous system cancers.

What Patients Should Know

The results are encouraging, but they are early.

This was a small study, and it compared patients to a matched group rather than a randomized trial. The approach also led to a higher rate of radiation-related changes in the brain, which in some cases required additional care.

Researchers say these findings highlight both the promise and the need for careful next steps.

For patients and families facing glioblastoma, the study points to a new strategy. Instead of treating all patients the same way, doctors may be able to tailor radiation based on where each patient’s cancer is most likely to return.

What Comes Next

The next step is to test this approach in a larger, multi-center study.

Researchers are working to move the concept into a trial through the NRG Oncology network, a national research group that leads large cancer clinical trials across institutions. These studies are designed to confirm whether promising early results hold true in a broader group of patients.

“Moving this into a larger trial is what will tell us if this approach can truly change care,” Shukla said. “That is the path to making a difference for patients.”

At the Graham Cancer Center, ground-breaking cancer research is every-day reality. Learn more about our robust pharmaceutical clinical trials program.